Lipidsenkende Mittel

  • Gerald Klose
  • Ulrich Schwabe


Seit acht Jahren sind die Statine die dominierende Gruppe der lipidsenkenden Arzneimittel. Diese Entwicklung beruht im wesentlichen auf ihrer hervor-ragenden Wirkung in der Prävention der koronaren Herzkrankheit.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arzneimittelkommission der deutschen Ärzteschaft (1999): Empfehlungen zur Therapie von Fettstoffwechselstörungen. Arzneiverordnung in der Praxis, Sonder-heftl, 2. Aufl.: 1–1.Google Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (2004): Myopathien bzw. Leberreaktionen unter Ezetimib (Ezetrol®) (Aus der UAW-Datenbank). Scholar
  3. Assmann G, Cullen P, Schulte H (2002): Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105: 310–315.PubMedCrossRefGoogle Scholar
  4. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ et al. for the Ezetimibe Study Group (2003): Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 107:2409–2415.PubMedCrossRefGoogle Scholar
  5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy — Thrombolysis in Myocar-dial Infarction 22 Investigators (2004): Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504.PubMedCrossRefGoogle Scholar
  6. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP et al. (2002): Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40:2125–2134.PubMedCrossRefGoogle Scholar
  7. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R et al. (2003): European Guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart Journal 24:1601–1610.CrossRefGoogle Scholar
  8. De Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD et al. (2004): Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z Trial. JAMA Aug 30 [Epub ahead of print].Google Scholar
  9. De Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N (1999): Mediter-ranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Circulation 99:779–785.PubMedCrossRefGoogle Scholar
  10. Downs JR, Clearfïeld M, Weis S, Whitney E, Shapiro DR et al. (1998): Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279:1615–1622.PubMedCrossRefGoogle Scholar
  11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001): Executive summary of the third report of the national cholesterol education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–2497.CrossRefGoogle Scholar
  12. Fux R, Möricke K, Gundel UF, Hartmann R, Gleiter CH (2004): Ezetimibe and statinassociated myopathy. Ann Intern Med 140:671–672.PubMedGoogle Scholar
  13. Gagné C, Gaudet D, Bruckert E for the Ezetimibe Study Group (2002): Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105:2469–2475.PubMedCrossRefGoogle Scholar
  14. Heart Protection Study Collaborative Group (2002): MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.CrossRefGoogle Scholar
  15. Helsinki Heart Study (1987): Primary-prevention trial with gemfibrozil in middleaged men with dyslipidemia. N Engl J Med 317:1237–1245.CrossRefGoogle Scholar
  16. Jenkins DJA, Kendall CWC, Marchie A, Faulkner DA, Wong JMW et al. (2003): Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290:502–510.PubMedCrossRefGoogle Scholar
  17. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV et al. Ezetimibe Study Group (2003): Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24: 729–741.PubMedCrossRefGoogle Scholar
  18. Law MR, Wald NJ, Rudnicka AR (2003): Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Brit Med J 326:1423–1430.PubMedCrossRefGoogle Scholar
  19. Lipid Research Clinics Program (1984): Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease. II. Relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:351–364,365–374.CrossRefGoogle Scholar
  20. Melani L, Mills R, Hassman D, Lipetz R, Lipka L et al. Ezetimibe Study Group (2003): Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 24:717–782PubMedCrossRefGoogle Scholar
  21. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators (2004): Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071–1080.PubMedCrossRefGoogle Scholar
  22. Pearson TA (1998): Lipid-lowering therapy in low risk patients. JAMA 279: 1659–1661.PubMedCrossRefGoogle Scholar
  23. Pyörälä K, De Backer G, Graham I, Pole-Wilson P, Wood D (1994): Prevention of coronary heart disease in clinical practice. Eur Heart J 15:1300–1331.PubMedGoogle Scholar
  24. Pyörälä K, Pedersen RT, Kjekshus J, Faergeman O, Olsson AG et al. (1997): Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 20:614–620.PubMedCrossRefGoogle Scholar
  25. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. for The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group (1999): Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410–418.PubMedCrossRefGoogle Scholar
  26. Sacks FM (2002): Low-density lipoprotein lowering therapy: An analysis of the options. J Am Coll Cardiol 40:2135–2138.PubMedCrossRefGoogle Scholar
  27. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD et al (1996): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335:1001–1009.PubMedCrossRefGoogle Scholar
  28. Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389.Google Scholar
  29. Sever SP, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. (2003): Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158.PubMedCrossRefGoogle Scholar
  30. Shepherd J, Blaun GJ, Murphy MB et al. (2002): Pravastatin in elderly individuals at risk of vascular disease (PROSPER), a randomised controlled trial. Lancet 360: 1623–1630.PubMedCrossRefGoogle Scholar
  31. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR et al. for the West of Scotland Coronary Prevention Study Group (1995): Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301–1307.PubMedCrossRefGoogle Scholar
  32. SIGN Publication Number 40 (1999): Lipids and the Primary Prevention of Coronary Heart Disease. SIGN Secretariat, Royal College of Physicians, 9 Queen Street, Edinburgh EH2 1JQ.Google Scholar
  33. SIGN Publication Number 41 (2000): Secondary Prevention for Coronary Heart Disease following Myocardial Infarction. SIGN Secretariat, Royal College of Physicians, 9 Queen Street, Edinburgh EH2 1JQ.Google Scholar
  34. Stamler J, Wentworth D, Neaton JD (1986): Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256:2823–2828.PubMedCrossRefGoogle Scholar
  35. Stein E (2001): Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J Suppl. 3(Suppl. E): El 1–E16.Google Scholar
  36. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN (2002): ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106:2055–2060.PubMedCrossRefGoogle Scholar
  37. The ALLHAT Officers and Coördinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288: 2998–3007.CrossRefGoogle Scholar
  38. The Bezafibrate Infaction prevention (BIP) Study Group (2000): Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infaction Prevention (BIP) study. Circulation 102:21–27.CrossRefGoogle Scholar
  39. The International Task Force for Prevention of Coronary Heart Disease (2003): www.chd-taskforce.deGoogle Scholar
  40. The Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Study Group (1998): Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–1357.CrossRefGoogle Scholar
  41. van Wissen S, Smilde TJ, de Groot E, Hutten BA, Kastelein JJ, Stalenhoef AF (2003): The significance of femoral intima-media thickness and plaque scoring in the atorvastatin versus simvastatin on atherosclerosis progression (ASAP) study. Eur J Cardiovasc Prev Rehabil 10:451–455.CrossRefGoogle Scholar
  42. Wiesner G, Grimm J, Bittner E (1999): Zum Herzinfarktgeschehen in der Bundesrepublik Deutschland: Pravalenz, Inzidenz, Trend, Ost-West-Vergleich. Gesundheitswesen 61(Sonderheft 2): S72–S78.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Gerald Klose
    • 1
  • Ulrich Schwabe
    • 2
  1. 1.Medizinische KlinikZentralkrankenhaus links der WeserBremen
  2. 2.Pharmakologisches Institut der Universität HeidelbergHeidelberg

Personalised recommendations